TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA has approved tiratricol (Emcitate) for peripheral thyrotoxicosis in patients with MCT8 deficiency (Allan-Herndon-Dudley syndrome), the first approved treatment for the rare X-linked genetic disorder. The once-daily liquid lowered excess thyroid hormone levels and improved cardiovascular and metabolic symptoms in two clinical trials.
The FDA on Monday approved tiratricol (Emcitate) to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, the first approved therapy for the rare genetic disorder, the agency announced on September 29, 2026. The thyroid hormone receptor agonist is indicated for adults and children with the condition, also known as Allan-Herndon-Dudley syndrome, which causes severe neurodevelopmental impairment and chronic strain on the heart and metabolism.
MCT8 deficiency is a rare, life-limiting, X-linked disorder caused by mutations in the SLC16A2 gene that primarily affects males. The mutations disrupt the MCT8 cell-surface transporter, leaving the central nervous system deprived of thyroid hormone while peripheral tissues are overexposed to active T3. According to the FDA, this dual imbalance often leaves patients unable to sit or walk independently while causing persistent peripheral thyrotoxicosis.
The approval was supported by two studies: the randomized, placebo-controlled ReTRIACt trial, which enrolled 20 participants ages 5 to 31, and an open-label trial of 46 participants ranging from 10 months to 66.8 years old. Across both studies, tiratricol lowered excess blood thyroid hormone levels and improved cardiovascular and metabolic symptoms affected by thyroid levels, such as systolic blood pressure and heart rate.
Tiratricol is administered once daily as a liquid suspension, given orally or through a feeding tube for patients with swallowing difficulties. The most common adverse effects include diarrhea, vomiting, rash, and hyperhidrosis. The label carries a boxed warning stating the drug is not intended for weight loss or obesity, and prescribing information cautions against use in patients with primary hyperthyroidism or alongside other thyroid medications. The label also warns of risks including thyrotoxicosis and interference with laboratory tests measuring T3 levels. Drugmaker Egetis Therapeutics said the drug will be available in the U.S. within 8 to 10 weeks.
Why This Approval Matters for Families
Before this approval, physicians in the U.S. had no FDA-cleared treatment option for MCT8 deficiency, a disorder that combines profound neurodevelopmental disability with dangerous chronic thyroid hormone excess in peripheral tissues. The ongoing cardiovascular and metabolic stress from untreated peripheral thyrotoxicosis is a major source of illness in these patients, and the trials showed tiratricol can reduce that burden.
The drug’s mechanism addresses the root problem of the disease: because the MCT8 transporter is the defective element, standard thyroid hormone therapy cannot reach cells effectively. Tiratricol’s ability to bypass that transporter gives clinicians a tool that previously did not exist.
How the Drug Bypasses the Defect
The core challenge in MCT8 deficiency is that the very protein needed to move thyroid hormone into cells — the MCT8 transporter — is the one that is not working. Tiratricol sidesteps this because its active ingredient can enter cells on its own without relying on the broken transporter, according to the FDA, which leads to a decrease in elevated blood thyroid hormone levels.
The clinical evidence base supporting approval spans a wide age range, from infants as young as 10 months in the open-label study to adults in their sixties, reflecting that MCT8 deficiency is a lifelong condition requiring chronic management.
“The challenge in treating MCT8 deficiency has always been that the protein needed to deliver thyroid hormone into cells is the one that isn’t working. This drug sidesteps that problem, as its active ingredient, tiratricol, can enter cells on its own without relying on the broken transporter, leading to a decrease in the elevated blood thyroid hormone levels.”
— Hylton Joffe, MD, MMSc, FDA Center for Drug Evaluation and Research
What the Trials Did Not Show
The FDA’s announcement and trial descriptions focus on reductions in blood thyroid hormone levels and improvements in cardiovascular and metabolic measures such as systolic blood pressure and heart rate. The extent to which tiratricol affects the neurodevelopmental impairment characteristic of MCT8 deficiency — such as the ability to sit or walk independently — is not addressed in the approval announcement, and any long-term neurodevelopmental outcomes remain unclear.
Pricing, insurance coverage details, and availability outside the U.S. were not specified in the announcement beyond Egetis Therapeutics’ statement of a U.S. launch within 8 to 10 weeks.
Launch Timeline and Clinical Uptake
Egetis Therapeutics said tiratricol will be available in the U.S. within 8 to 10 weeks of the approval, meaning patients and clinicians could begin accessing the drug in late 2026. Prescribers will need to follow label precautions, including avoiding co-use with other thyroid medications and interpreting laboratory T3 tests carefully given the risk of assay interference.
Longer-term, physicians and researchers are likely to monitor how the drug performs in real-world use across the full age spectrum of MCT8 deficiency, including infants treated early and adults on chronic therapy, and whether earlier treatment influences disease trajectory.
Key Questions
What is MCT8 deficiency?
MCT8 deficiency, also called Allan-Herndon-Dudley syndrome, is a rare, life-limiting X-linked genetic disorder caused by mutations in the SLC16A2 gene. It primarily affects males and disrupts thyroid hormone transport into cells, causing severe neurodevelopmental impairment and peripheral thyrotoxicosis.
What is tiratricol (Emcitate) and how is it taken?
It is a thyroid hormone receptor agonist taken once daily as a liquid suspension, either orally or via feeding tube. It is approved for adults and children with MCT8 deficiency.
How effective was tiratricol in clinical trials?
In the placebo-controlled ReTRIACt trial (20 participants) and an open-label study (46 participants), tiratricol lowered excess blood thyroid hormone levels and improved cardiovascular and metabolic symptoms such as systolic blood pressure and heart rate, according to the FDA.
What are the main risks and warnings?
Common side effects include diarrhea, vomiting, rash, and excessive sweating. The label carries a boxed warning that the drug is not for weight loss or obesity, and it cautions against use in primary hyperthyroidism or with other thyroid medications, and notes risks of thyrotoxicosis and interference with T3 lab tests.
When will the drug be available?
Egetis Therapeutics said tiratricol will be available in the U.S. within 8 to 10 weeks of the September 2026 approval.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
